The new NICE guidance recommends that most people should now be offered metformin along with an SGLT-2 inhibitor from the start, while also advising that they get a slow-release formulation of ...

The long months without stable leadership at the CDC in the US look set to continue, as the Trump administration confirms that NIH Director Jay Bhattacharya will step in as acting director of the ...

Managing bipolar I disorder (BD-I) is a long-term commitment, and factors such as symptoms and side effects influence ...

The agreement gives MSD (known as Merck & Co in the US and Canada) access to the Mayo Clinic Platform architecture – which covers de-identified laboratory results, medical imaging, clinical notes, ...

Traditional virtual engagement often forces patients into a corporate mould – a 60-minute, high-pressure web meeting where the loudest voice dominates and key insights are lost to language or time ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...

In its new update, Moderna said that it had held a meeting with the FDA's Center for Biologics Evaluation and Research (CBER) and agreed on a "revised regulatory approach" that has allowed the review ...

Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock ...

The analysis by property advisory firm Knight Frank found a 22% increase in the number of life sciences companies domiciled in the UK between 2019 and the end of 2025, to a total of 15,436.

Novartis is on course to expand the label for its recently approved oral BTK inhibitor Rhapsido, after chalking up a win in chronic skin disorder chronic inducible urticaria (CINDU).

The three-year study – led by mental health data science company Akrivia Health in partnership with Cardiff University – will ...